目的 探讨牛黄降压片联合硝苯地平缓释片治疗原发性高血压的临床疗效。方法 选取2019年3月—2019年6月在成都市第七人民医院治疗的原发性高血压患者86例，根据用药差别分为对照组（43例）和治疗组（43例）。对照组口服硝苯地平缓释片，20 mg/次，2次/d；治疗组在对照组基础上口服牛黄降压片，2 g/次，1次/d。两组患者均经4周治疗。观察两组患者临床疗效，同时比较治疗前后两组患者血压变化，SPIEGEL、SAS、SDS和GQOL-74评分，及血清同型半胱氨酸（Hcy）、血管性血友病因子（vWF）、可溶性细胞间黏附分子-1（sICAM-1）、可溶性凝集素样氧化低密度脂蛋白受体1（sLOX-1）、血管紧张素Ⅱ（AngⅡ）水平。结果 治疗后，对照组和治疗组临床有效率分别为81.40%和97.67%，两组比较差异具有统计学意义（P<0.05）。经治疗，两组收缩压（SBP）、舒张压（DBP）均显著下降（P<0.05），且治疗组患者血压水平明显好于对照组患者（P<0.05）。经治疗，两组患者SPIEGEL评分、SAS评分和SDS评分明显降低（P<0.05），但是GQOL-74评分明显升高（P<0.05），且治疗组患者这些评分明显好于对照组（P<0.05）。经治疗，两组血清Hcy、vWF、sICAM-1、sLOX-1、AngⅡ水平均明显降低（P<0.05），且治疗组明显低于对照组（P<0.05）。结论 牛黄降压片联合硝苯地平缓释片治疗原发性高血压可有效控制血压水平，改善患者负面情绪、睡眠及生活质量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Niuhuang Jiangya Tablets combined with nifedipine in treatment of essential hypertension. Methods Patients (86 cases) with essential hypertension in Chengdu Seventh People's Hospital Chinese from March 2019 to June 2019 were divided into control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were po administered with Nifedipine Sustained-release Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Niuhuang Jiangya Tablets on the basis of the control group, 2 g/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the change of blood pressure, the scores of SPIEGEL, SAS, SDS and GQOL-74, SAQ and GQOLI-74 scores, the serum levels of Hcy, vWF, sICAM-1, sLOX-1 and AngⅡ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.40% and 97.67% respectively, and there were differences between two groups (P<0.05). After treatment, the SBP and DBP in two groups was significantly decreased (P<0.05), and the blood pressure in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of SPIEGEL, SAS and SDS in two groups were significantly decreased (P<0.05), but the GQOL-74 scores were significantly increased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum levels of Hcy, vWF, sICAM-1, sLOX-1, and AngⅡ in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Niuhuang Jiangya Tablets combined with nifedipine in treatment of essential hypertension can effectively control blood pressure level, improve patients' negative emotions, sleep and quality of life, which has a certain clinical application value.

R972